Every article, report, and earnings note where DHR appears.
Danaher is showing a credible operational recovery, with stronger core growth, higher margins, and raised EPS guidance. The stock still looks fairly expensive, keeping the rating at Hold despite improving fundamentals.
Davion Healthcare Plc is set to list on Nasdaq on 2026-10-22, with a price range not disclosed and a market cap of $252,750,000. The company is coming public as a direct listing, so there is no traditional underwritten IPO bookbuild or IPO proceeds. The bull case is a pre-revenue medtech story with multiple registered products and a consumer OTC model. The bear case is that the stock starts trading without the cushion of an IPO raise, while cash remains extremely thin and execution risk is high.
A seven-stock countdown explores quality across life sciences tools, from challenged platforms to profitable analytical, diagnostic, and research franchises.
Danaher Corporation (DHR) rises after a sharp post-earnings selloff as investors reassess its Q2 beat, softer core-growth guidance, and delayed bioprocessing revenue. The rebound reflects a reset in expectations rather than a new catalyst, with light volume suggesting limited confirmation.
Danaher Corporation (DHR) rises after investors step back in following a sharp post-earnings selloff. The company beat quarterly EPS estimates but trimmed full-year revenue growth guidance, sparking a rebound as traders viewed the weakness as timing-related rather than a broken business.
Danaher Corporation (DHR) falls sharply after earnings as investors focus on weaker-than-expected forward guidance rather than the quarter’s beat on revenue and EPS. The selloff reflects a valuation reset for a premium stock priced for stronger growth.
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
A seven-stock healthcare countdown spans telehealth, devices, life-science tools, diagnostics, distribution, and managed care, with HIMS, BDX, TMO, DHR, and ABT in focus.
Danaher Corporation (DHR) fell 5.4% after its latest earnings report, even with an EPS beat and a modest guidance raise. Investors focused on soft revenue, weak core growth, and mixed segment performance, especially in Diagnostics, which outweighed the company’s strong margins and cash flow.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate DHR ReportCancel anytime